Golvatinib (E7050, E-7050, CAS: 928037-13-2) is a small molecule tyrosine kinase inhibitor that has shown potential as a cancer treatment. It is being developed for the treatment of various types of cancer, including hepatocellular carcinoma, gastric cancer, and renal cell carcinoma. In this article, we will discuss the chemical properties of Golvatinib, its health benefits, potential effects, mechanism of action, safety profile, dosing information, and more.
Chemical Properties: The chemical name of Golvatinib is N-(4-fluoro-2-methyl-1-(1-(2-(4-(5-methyl-2-((4-(methylsulfonyl)phenyl)amino)pyrimidin- 5-yl)ethyl)piperidin-4-yl)indolin-6-yl)phenyl)-3-(trifluoromethyl)benzamide. Its molecular formula is C33H37F4N7O3S, and its formula weight is 697.76 g/mol. The CAS number of Golvatinib is 928037-13-2.
Top Ten Keywords from Google and Synonyms:
Synonyms:
Health Benefits: Golvatinib has shown potential health benefits as a cancer treatment. It works by inhibiting tyrosine kinases, which are enzymes involved in cell signaling pathways that can promote cancer growth and survival. By blocking these proteins, Golvatinib may help to slow or stop the growth of cancer cells, making it a promising therapy for various types of cancer.
Potential Effects: Golvatinib has been studied in preclinical and clinical trials for its potential effects on cancer. Some of its key effects include:
Product Mechanism: Golvatinib works by inhibiting tyrosine kinases, which are involved in various cellular signaling pathways. These kinases can activate other proteins inside the cell, leading to changes in cell growth, proliferation, and survival. By blocking tyrosine kinases, Golvatinib can disrupt these pathways and potentially slow or stop the growth of cancer cells.
Safety: Like all drugs, Golvatinib has some potential safety concerns. However, the safety of the product is still being investigated and should not be considered as a fully approved medication yet. Some of the known safety issues include:
Side Effects: Some of the possible side effects of Golvatinib include fatigue, nausea, vomiting, diarrhea, decreased appetite, and hair loss. More serious adverse events reported in clinical trials include hypertension, blood clots, and liver dysfunction. It is, therefore, essential for healthcare providers to monitor patients closely when they are on this medication.
Dosing Information: The optimal dosages of Golvatinib are still being studied but initial reports suggest that 600 mg dose might be a standard dose.
Conclusion: In conclusion, Golvatinib is a promising small molecule tyrosine kinase inhibitor that has shown potential as a cancer treatment. It works by inhibiting tyrosine kinases, which are involved in various cellular signaling pathways that regulate cell growth and survival. Although still in early stages of clinical development, Golvatinib has shown efficacy in reducing chemotherapy resistance, enhanced radiosensitivity and reduced tumor cell proliferation
